Last updated: September 8, 2026
Levalbuterol tartrate is a mature, genericized short-acting beta-2 agonist marketed primarily through Xopenex HFA and generic inhalation aerosol products. The product has limited remaining brand pricing power, no biologic or biosimilar exposure, and a market increasingly shaped by generic substitution, pharmacy-channel access, inhaler manufacturing capacity, and competition from albuterol and newer maintenance therapies.
Public companies generally do not disclose revenue for levalbuterol tartrate as a standalone product. Financial analysis therefore relies on product-level disclosures, FDA approval records, prescription-market data, and the reported performance of the branded Xopenex franchise.
What is levalbuterol tartrate and which products contain it?
Levalbuterol is the R-enantiomer of albuterol. Levalbuterol tartrate is used in metered-dose inhalation products, while levalbuterol hydrochloride is used in several inhalation-solution products.
The principal branded product is Xopenex HFA, a metered-dose inhaler containing 45 micrograms of levalbuterol tartrate per actuation. The product is indicated for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease, including asthma. The FDA-approved label recommends two inhalations three times daily for adults and adolescents, subject to clinical response and tolerability (FDA, 2023a).
| Product |
Active ingredient |
Dosage form |
Primary market status |
| Xopenex HFA |
Levalbuterol tartrate |
Metered-dose inhaler |
Branded product with generic competition |
| Generic levalbuterol tartrate inhalation aerosol |
Levalbuterol tartrate |
Metered-dose inhaler |
Approved generic market |
| Xopenex inhalation solution |
Levalbuterol hydrochloride |
Nebulizer solution |
Separate salt and dosage-form market |
| Generic levalbuterol inhalation solution |
Levalbuterol hydrochloride |
Nebulizer solution |
Mature generic market |
The distinction between levalbuterol tartrate and levalbuterol hydrochloride matters for patent, regulatory, and commercial analysis. The HFA inhaler market is not interchangeable with the nebulizer-solution market for purposes of formulation, device, manufacturing, or Orange Book analysis.
When did levalbuterol tartrate lose exclusivity?
Levalbuterol tartrate lost practical market exclusivity after FDA approval of generic inhalation aerosol products. The original Xopenex HFA franchise no longer has the characteristics of a protected single-source product.
Xopenex HFA was approved under NDA 021730. The product’s original regulatory exclusivity period has expired, and generic versions have entered the U.S. market through the ANDA pathway. FDA approval of a generic inhaler requires pharmaceutical equivalence, bioequivalence or equivalent clinical performance as applicable, device-related controls, and manufacturing compliance (FDA, 2023b).
The commercial exclusivity timeline is:
| Milestone |
Timing |
Commercial effect |
| Xopenex HFA FDA approval |
2005 |
Launch of levalbuterol tartrate HFA inhaler |
| Original regulatory exclusivity |
Expired |
Brand no longer protected by FDA exclusivity |
| Generic ANDA approvals |
Later market period |
Entry of generic inhalation aerosols |
| Current market |
Mature generic phase |
Price compression and formulary substitution |
The exact date on which a particular patent ceased to block generic entry depends on the patent, pediatric extensions, litigation settlements, and the applicant’s approval status. For commercial purposes, the market has already transitioned from originator exclusivity to multi-source competition.
What patents protect levalbuterol tartrate products?
The relevant patent estate has historically included composition, stereochemistry, formulation, aerosol delivery, canister, valve, and manufacturing claims. The commercial value of the estate is now concentrated in product-specific formulation and device claims rather than in basic molecule protection.
Potential patent categories include:
- Active-ingredient and stereochemical patents. These addressed the use of the R-enantiomer of albuterol and related pharmaceutical forms.
- Inhalation-formulation patents. These covered hydrofluoroalkane propellant systems, excipients, suspension stability, particle-size distribution, and dose uniformity.
- Device patents. These addressed metering valves, actuator geometry, canister compatibility, and dose delivery.
- Method-of-use patents. These covered treatment of bronchospasm, asthma, and reversible obstructive airway disease.
- Manufacturing patents. These may cover suspension processing, filling, valve crimping, and quality-control methods.
The strongest remaining barriers are generally technical and operational. A generic company must reproduce a consistent delivered dose, aerodynamic particle-size distribution, spray pattern, valve performance, and stability profile. Those requirements raise development costs, but they do not create the same barrier as an unexpired composition-of-matter patent.
The FDA Orange Book is the controlling public source for patents listed against an approved drug product. Orange Book listings must be reviewed at the NDA-product level because patents listed against Xopenex HFA may not apply to levalbuterol hydrochloride nebulizer products or to every generic dosage form (FDA, 2024).
What is the Orange Book status of Xopenex HFA?
Xopenex HFA is an approved prescription inhalation product listed in FDA drug databases under NDA 021730. Its patent status should be evaluated by examining the current Orange Book entries for the specific NDA, including patent numbers, expiration dates, pediatric extensions, and any approved-use codes.
The commercial significance of Orange Book patents is lower than it was during the brand’s launch period because generic levalbuterol tartrate inhalation aerosol products are already available. Any surviving listed patents would more likely affect a particular use, formulation, or device configuration than the entire levalbuterol tartrate market.
An Orange Book listing does not by itself establish infringement liability. A generic applicant can file a Paragraph IV certification challenging listed patents, or a Paragraph III certification agreeing to wait until patent expiration. The practical outcome depends on the patent claims, the ANDA product design, litigation, and any settlement restrictions.
Which companies are challenging or competing with Xopenex HFA?
The competitive set includes generic manufacturers of levalbuterol tartrate inhalation aerosol and suppliers of alternative short-acting bronchodilators.
The principal competitive groups are:
- Generic inhaler manufacturers filing or commercializing ANDA products.
- Albuterol HFA manufacturers, including large generic suppliers.
- Nebulizer-solution manufacturers supplying levalbuterol hydrochloride.
- Combination-product manufacturers offering inhaled corticosteroid and bronchodilator therapies.
- Pharmacy benefit managers and wholesalers that influence substitution and channel access.
The most important economic competitor is albuterol, not another levalbuterol product. Albuterol has broader utilization, deeper generic competition, and stronger formulary familiarity. Levalbuterol can retain demand among prescribers seeking the R-enantiomer or patients who experience tolerability or response differences, but those clinical distinctions have not supported durable brand-level pricing after generic entry.
What Paragraph IV challenges affect levalbuterol tartrate?
Paragraph IV risk is primarily relevant to the period when Xopenex HFA patents could have delayed ANDA approval. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or not infringed. If the NDA holder files suit within the statutory period, FDA approval may be stayed for up to 30 months, subject to statutory exceptions and court developments.
For a mature product such as levalbuterol tartrate inhalation aerosol, the major commercial question is no longer whether the first generic challenger will enter. The relevant questions are:
- Whether additional generic suppliers can obtain approval.
- Whether any remaining device or formulation patent limits a specific product.
- Whether supply constraints allow approved generics to gain market share.
- Whether a generic product receives preferred formulary placement.
- Whether an authorized generic or brand-linked generic suppresses pricing.
No biosimilar pathway applies. Levalbuterol tartrate is a chemically synthesized small molecule, so competition proceeds through ANDAs rather than abbreviated biologics applications.
How strong is the levalbuterol tartrate patent estate?
The patent estate is commercially weak at the molecule level and moderate at the product-engineering level.
| Estate category |
Current strength |
Reason |
| Core molecule |
Low |
Mature small-molecule technology and expired original protection |
| Stereochemistry |
Low to moderate |
Historical importance, but limited current exclusivity value |
| HFA formulation |
Moderate |
Requires technical replication but faces generic-development pathways |
| Inhaler device |
Moderate |
Device claims may affect particular designs |
| Method of use |
Low |
Broad asthma and bronchospasm claims are difficult to preserve commercially |
| Manufacturing process |
Moderate |
Can create operational friction without blocking the whole market |
The estate does not support a strong long-term monopoly thesis. Its residual value lies in manufacturing know-how, regulatory execution, and supply reliability.
What is the financial trajectory for levalbuterol tartrate?
The financial trajectory is mature-to-declining for branded Xopenex HFA and stable-to-competitive for the overall active-ingredient market.
Originator revenue declined after generic entry because:
- Brand-only pricing ended.
- Formularies shifted toward lower-cost substitutes.
- Albuterol remained the dominant short-acting bronchodilator.
- Generic inhaler suppliers gained access to retail and institutional channels.
- The clinical advantage of levalbuterol did not justify a sustained premium for most payers.
Sunovion and its predecessor Sepracor reported Xopenex-related sales in historical corporate filings, but later public company disclosures generally did not provide a clean, current revenue line for levalbuterol tartrate alone. The absence of standalone reporting prevents a reliable current global revenue estimate from public filings (Sunovion Pharmaceuticals, 2016; Sumitomo Pharma, 2023).
The revenue model is therefore best understood through market structure:
| Financial driver |
Direction |
Effect |
| Generic entry |
Negative for brand |
Reduces price and share |
| Generic supplier count |
Negative for all suppliers |
Increases price competition |
| Respiratory-season demand |
Positive but variable |
Raises volume during exacerbation periods |
| Formulary preference |
High impact |
Determines substitution and net price |
| Inhaler capacity |
Potentially positive for suppliers |
Supply shortages can temporarily support share |
| Brand clinical familiarity |
Supportive |
Preserves residual prescriptions |
| Albuterol competition |
Negative |
Limits price and volume expansion |
The generic market can remain commercially viable despite low unit prices because inhaler manufacturing complexity limits the number of effective competitors relative to oral tablets.
What generic launch scenarios exist for levalbuterol tartrate?
Three launch scenarios are commercially relevant.
Single additional generic entrant
A single new entrant can gain meaningful share if incumbents face supply shortages or lack preferred payer contracts. Price erosion is usually less severe than in a market with many tablet suppliers, but net pricing still declines.
Multi-source generic competition
Several approved suppliers create stronger substitution pressure. Pharmacies and payers can shift patients based on acquisition cost, rebate structure, and product availability. Brand retention falls unless the brand has a differentiated device, superior supply, or contract advantage.
Supply-constrained market
Inhaler manufacturing failures, canister or valve shortages, or regulatory manufacturing observations can temporarily increase demand for the brand or a limited number of generics. These events can improve short-term volume without restoring long-term exclusivity.
What manufacturing and intellectual-property barriers remain?
The principal barriers are inhaler-specific rather than molecule-specific. Manufacturers must control:
- Suspension homogeneity.
- Valve metering accuracy.
- Delivered-dose uniformity.
- Aerodynamic particle-size distribution.
- Canister and actuator compatibility.
- Propellant and excipient stability.
- Microbial and particulate controls.
- Container-closure integrity.
- Device-use instructions and human-factors requirements.
These barriers can delay launches and reduce the number of commercially reliable suppliers. They do not eliminate generic substitution because FDA guidance and established inhaler-development pathways provide a regulatory route for equivalent products (FDA, 2023b).
Geographic protection is also limited. U.S. patents and FDA approvals do not establish exclusivity in Europe, Canada, Japan, or emerging markets. Each jurisdiction has separate patent, regulatory, pricing, and reimbursement systems. The U.S. market is the most relevant for Orange Book and Paragraph IV analysis, while international revenue depends more heavily on local registration and tender pricing.
How does levalbuterol tartrate compare with albuterol?
| Attribute |
Levalbuterol tartrate |
Albuterol |
| Pharmacology |
R-enantiomer of albuterol |
Racemic mixture |
| Primary role |
Rescue bronchodilation |
Rescue bronchodilation |
| Market maturity |
Mature generic |
More mature generic |
| Brand pricing power |
Limited |
Limited |
| Generic competition |
Present |
Broad and entrenched |
| Clinical differentiation |
Potential tolerability or response differences |
Standard of care for many patients |
| Commercial outlook |
Stable niche with price pressure |
Larger volume, lower unit economics |
| Patent value |
Device and formulation focused |
Mostly mature generic platform |
Levalbuterol can retain value in selected patients and institutions, but it has not displaced albuterol as the default short-acting bronchodilator.
What is the regulatory status of levalbuterol tartrate?
Xopenex HFA remains an FDA-approved prescription inhalation product, subject to labeling, manufacturing, post-market safety, and current good manufacturing practice requirements. Generic products are approved through ANDAs and must meet FDA standards for pharmaceutical equivalence and therapeutic substitutability as applicable.
Safety considerations include paradoxical bronchospasm, cardiovascular effects, hypokalemia, and excessive use. These risks are addressed in the FDA-approved labeling and apply to commercial positioning, prescribing, and pharmacovigilance (FDA, 2023a).
Key Takeaways
- Levalbuterol tartrate is a mature, genericized small-molecule inhaler market.
- Xopenex HFA is no longer protected by practical product-level exclusivity.
- The core molecule has limited current patent value.
- Remaining barriers center on HFA formulation, inhaler devices, quality control, and manufacturing capacity.
- Paragraph IV litigation is mainly a historical entry mechanism rather than the central current market risk.
- No biosimilar pathway applies because levalbuterol tartrate is a small molecule.
- Brand revenue has structurally declined after generic entry, and public companies do not consistently disclose current standalone levalbuterol revenue.
- Albuterol remains the principal commercial competitor.
- Generic profitability depends on supply reliability, payer access, and inhaler manufacturing execution.
- The market outlook is stable in volume but pressured in price and brand share.
FAQs About Levalbuterol Tartrate Market and Patent Risk
Is levalbuterol tartrate still under patent protection?
The original molecule-level exclusivity has expired. Any remaining patent relevance is more likely to involve a specific inhaler formulation, device, manufacturing process, or labeled use.
Is Xopenex HFA still a branded product?
Yes. Xopenex HFA remains the reference branded product, but it competes with generic levalbuterol tartrate inhalation aerosol products.
Does levalbuterol tartrate have biosimilar competition?
No. Levalbuterol tartrate is a chemically synthesized small molecule and competes through generic ANDAs, not biosimilar applications.
Can generic manufacturers substitute levalbuterol for albuterol?
No. Levalbuterol and albuterol are different active pharmaceutical products. Substitution depends on state pharmacy law, product labeling, payer policy, and prescriber authorization.
What is the principal investment risk in levalbuterol tartrate?
The main risk is continued price erosion from generic competition, compounded by albuterol substitution and limited brand differentiation. The main upside is temporary share or pricing improvement caused by generic supply disruption or manufacturing constraints.
References
- U.S. Food and Drug Administration. (2023a). Xopenex HFA: Prescribing information.
- U.S. Food and Drug Administration. (2023b). Product-specific guidance for levalbuterol tartrate inhalation aerosol.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- Sunovion Pharmaceuticals Inc. (2016). Corporate and product information for Xopenex HFA.
- Sumitomo Pharma Co., Ltd. (2023). Annual report and pharmaceutical product disclosures.
